ARMISTICE CAPITAL, LLC

Armistice Capital, LLC operates as a New York-based hedge fund manager specializing in healthcare and biotechnology investing with a distinctive activist orientation that sets it apart from traditional long-only healthcare funds. The firm files 13F reports with the SEC under CIK #0001601086, providing quarterly transparency into its U.S. equity holdings that reflect its concentrated, catalyst-driven investment approach within the life sciences sector. Founded by Steven Boyd, Armistice Capital has established itself as a significant participant in small and mid-cap biotechnology investing, frequently acquiring substantial stakes in companies where the firm perceives opportunities to unlock value through corporate engagement, strategic repositioning, or catalyst realization. The firm's willingness to take activist positions and push for changes distinguishes its approach from passive healthcare sector funds. The New York headquarters positions Armistice within the concentrated ecosystem of healthcare-focused hedge funds, providing access to specialized research resources, industry consultants, and the network of biotechnology companies, pharmaceutical partners, and investment banks that characterize the sector. This location facilitates the deep industry relationships essential for biotechnology investing success. Armistice Capital maintains a relatively low public profile compared to larger activist funds, operating without a public-facing website while focusing resources on investment research and portfolio company engagement. This operational discretion reflects the sensitive nature of activist investing where public pronouncements may complicate strategic initiatives or corporate negotiations. Leadership centers on Steven Boyd as Founder, Managing Member, and Chief Investment Officer, who established the firm's specialized focus on healthcare and activist strategies. Boyd's investment approach combines deep sector expertise with willingness to engage actively with portfolio company management and boards to catalyze value creation. Keith Maher serves as Chief Financial Officer and Chief Compliance Officer, managing the operational and regulatory infrastructure supporting investment activities.

Armistice Capital employs a concentrated, activist-oriented investment strategy focused predominantly on the healthcare and biotechnology sectors, seeking companies with undervalued assets, upcoming clinical catalysts, or strategic optionality that active engagement might unlock. The firm's approach integrates fundamental biotechnology research with event-driven investing and shareholder activism. 13F Portfolio Composition analysis reveals substantial concentration in healthcare and biotechnology holdings, often featuring significant positions in small and mid-cap life sciences companies. The portfolio typically exhibits high conviction positioning where individual holdings may represent meaningful ownership stakes, enabling the firm to exert influence over corporate decision-making when engagement opportunities arise. The investment process emphasizes identifying companies with clinical-stage assets, approved products, or technology platforms trading below intrinsic value due to market inefficiency, execution challenges, or capital structure issues. Armistice seeks situations where active intervention—through board representation, strategic recommendations, or public pressure—may accelerate value realization beyond passive holding period returns. Top 10 Holdings Concentration typically reveals highly concentrated positioning characteristic of activist strategies, where meaningful ownership stakes are necessary to gain corporate access and influence strategic direction. This concentration creates significant position-level risk but enables the portfolio engagement that distinguishes activist returns from passive sector exposure. The firm frequently utilizes structured investments including convertible securities, warrants, and PIPE (Private Investment in Public Equity) transactions that provide downside protection or enhanced upside participation compared to common equity purchases. These structures reflect sophisticated capital deployment designed to optimize risk-adjusted returns in volatile biotechnology situations. Portfolio turnover characteristics run moderate to high, reflecting the catalyst-driven nature of biotechnology investing where position entry and exit often correspond to clinical trial results, regulatory decisions, or strategic transactions. The activist orientation may extend holding periods when corporate engagement initiatives require time to implement, though successful catalysts typically trigger position monetization. Sector Allocation History examination reveals persistent healthcare and biotechnology concentration rather than diversified sector rotation, reflecting the firm's specialized expertise and focused investment mandate.

Armistice Capital presents a specialized analytical case study in activist healthcare hedge fund management, where concentrated biotechnology positioning combines with active corporate engagement to create distinctive return characteristics. The firm's 13F filing history under CIK #0001601086 enables examination of portfolio evolution, position building patterns, and activist campaign development across market cycles. Historical Track Record simulation enables assessment of compounding behavior normalized to user-defined notional values, though users should recognize that 13F holdings represent only the long equity component of potentially more complex hedged positions. Understanding historical capital trajectory provides context for evaluating the activist biotechnology strategy's effectiveness. Sharpe Ratio and Sortino Ratio analysis quantify risk-adjusted return generation, revealing whether the concentrated activist approach delivers efficient risk utilization despite elevated volatility. The Sortino ratio may prove particularly relevant given the asymmetric return distributions characteristic of biotechnology investing. Simulated Growth Chart visualization enables examination of compounding patterns across market cycles and biotechnology sector rotations. Understanding performance during the 2015-2016 healthcare correction, the 2020 pandemic volatility, and subsequent periods provides insight into strategy resilience across varied market environments. Alpha Generation vs S&P 500 and sector-specific benchmark comparisons illuminate skill-based return contribution. Activist strategies should theoretically generate alpha through corporate engagement that accelerates value realization beyond passive holding returns. Quantitative analysis across market cycles validates or challenges this value proposition. The firm's concentrated biotechnology focus requires comparison against appropriate sector benchmarks rather than broad market indices. Healthcare-specific comparisons provide more relevant assessment of stock selection and activist value creation capabilities. A central analytical question for prospective allocators emerges: How does Armistice Capital's activist biotechnology approach perform across clinical trial outcome environments and healthcare sector rotations—and does the concentrated, engagement-driven strategy deliver risk-adjusted returns justifying its elevated volatility profile compared to diversified healthcare alternatives?

Armistice Capital's risk profile reflects the inherent volatility of concentrated biotechnology investing combined with the idiosyncratic risks associated with activist engagement strategies. The firm's specialized focus creates distinctive risk characteristics requiring careful assessment by prospective allocators. Volatility Profile assessment reveals elevated return dispersion characteristic of small and mid-cap biotechnology portfolios, where individual holdings may experience dramatic price movements based on clinical trial outcomes, regulatory decisions, or competitive developments. Binary events are common in biotechnology investing, with success or failure of key clinical trials often determining 50% or greater price movements in affected holdings. The concentrated positioning amplifies volatility characteristics, as meaningful positions in individual securities create portfolio sensitivity to company-specific events. While concentration enables the activist influence central to the investment strategy, it simultaneously increases return dispersion compared to diversified healthcare portfolios. Max Drawdown Depth analysis provides critical insight into capital preservation during sector-specific and market-wide stress periods. Biotechnology portfolios historically experience significant drawdowns during risk-off environments when investors reduce exposure to speculative growth assets. The 2015-2016 biotechnology correction and periodic sector rotations demonstrate potential drawdown magnitude. The Downside Capture Ratio may exhibit asymmetric characteristics, as activist value creation and structured investment terms may provide partial cushioning during broad market declines while clinical trial failures or regulatory setbacks create concentrated losses in affected positions. Activist strategy risks include unsuccessful corporate engagement attempts, management entrenchment, litigation exposure, and reputation considerations that may constrain future investment opportunities. The firm's influence depends on building credible relationships with boards and management teams, and failed campaigns may damage future engagement prospects. Regulatory and clinical trial risks represent sector-specific considerations, as FDA decisions, clinical setback, and changing reimbursement dynamics can fundamentally alter investment thesis regardless of activist involvement. Healthcare policy uncertainty introduces additional systematic risk affecting the entire portfolio. Liquidity risk warrants consideration given the small and mid-cap focus, as meaningful positions in less liquid securities may be difficult to exit efficiently during stressed markets or following adverse developments.